Evidence map›Paper›PMID 38839656›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2024

Hip fractures in patients with primary aldosteronism - a Swedish nationwide study.

Eleftheria Gkaniatsa, Tatiana Zverkova Sandström, Annika Rosengren, Penelope Trimpou, Andreas Muth, Gudmundur Johannsson, Oskar Ragnarsson

Abstract read
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eleftheria GkaniatsaDepartment of Endocrinology, Sahlgrenska University Hospital, 413 46, Gothenburg, Sweden. eleftheria.gkaniatsa@vgregion.se.ORCID http://orcid.org/0000-0002-2150-0499
Tatiana Zverkova SandströmHealth Metrics Unit, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Annika RosengrenDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 41650, Gothenburg, Sweden.
Penelope TrimpouDepartment of Endocrinology, Sahlgrenska University Hospital, 413 46, Gothenburg, Sweden.
Andreas MuthDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
Gudmundur JohannssonDepartment of Endocrinology, Sahlgrenska University Hospital, 413 46, Gothenburg, Sweden.
Oskar RagnarssonDepartment of Endocrinology, Sahlgrenska University Hospital, 413 46, Gothenburg, Sweden.

Funding

Gothenburg Society of Medicine nr 22/972512Hjärt-Lungfonden 2021-0345Swedish government and the county councils, the ALF-agreement Grant Number: 971027Swedish Research Council 2019-00193
6 · The paper itself

Abstract

In this large population-based matched cohort study, patients with primary aldosteronism were at increased risk of hip fracture, particularly subgroups traditionally considered at higher risk of osteoporosis such as women, patients older than 56 years at diagnosis, patients with established cardiovascular disease at diagnosis, and patients treated with MRA. PURPOSE: Previous studies suggest that primary aldosteronism (PA) is associated with dysregulated bone homeostasis. The aim of this study was to evaluate the incidence of hip fractures in patients with PA.

methodsWe studied a nationwide cohort of 2419 patients with PA (1997-2019) and 24 187 age and sex matched controls from the general population. Hip fractures were identified by ICD codes in the Swedish National Patient Register. We estimated hazard ratios (HRs) for incident hip fractures, adjusted for prior fractures, socioeconomic factors, diabetes, osteoporosis, hyperparathyroidism, and cardiovascular disease (CVD). Pairwise subgroup comparisons were performed by age (18-56 and > 56 years), sex, CVD at baseline, and treatment for PA.

resultsDuring a mean follow up of 8 ± 5 years, 64 (2.6%) patients had a hip fracture after being diagnosed with PA, compared to 401 (1.7%) controls. After adjustments, PA was associated with a 55% increased risk of hip fracture compared to controls (HR 1.55 [1.18-2.03]). HRs were increased in women (HR 1.76 [95% CI 1.24-2.52]), patients aged > 56 years (HR 1.62 [95% CI 1.21-2.17]), and patients with CVD at diagnosis (HR 2.15 [95% CI 1.37-3.37]). PA patients treated with adrenalectomy did not have higher risk than controls (HR 0.84 [95% CI 0.35-2.0]), while patients treated with mineralocorticoid receptor antagonists (MRA) retained a greater risk (HR 1.84 [95% CI 1.20-2.83]).

conclusionPA is associated with increased hip fracture risk, especially in women, patients diagnosed after the age of 56 years and patients with established CVD at diagnosis. Also, patients treated with MRA seem to have an increased risk of hip fractures, while adrenalectomy may be protective.

Indexed as

Hip FracturesHyperaldosteronismAdolescentAdultAgedAge FactorsCase-Control StudiesCohort StudiesFemaleHumansIncidenceMaleMiddle AgedMineralocorticoid Receptor AntagonistsOsteoporotic FracturesRegistriesMineralocorticoid Receptor AntagonistsHip fractureOsteoporosisPrimary aldosteronismPrimary hyperparathyroidism

Identifiers

PMID38839656
PMCPMC11364790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.